106 related articles for article (PubMed ID: 7672794)
1. Prognostic value of bcl-2 immunoreactivity in medullary thyroid carcinoma.
Viale G; Roncalli M; Grimelius L; Graziani D; Wilander E; Johansson H; Bergholm U; Coggi G
Hum Pathol; 1995 Sep; 26(9):945-50. PubMed ID: 7672794
[TBL] [Abstract][Full Text] [Related]
2. Prognostic value of N-myc immunoreactivity in medullary thyroid carcinoma.
Roncalli M; Viale G; Grimelius L; Johansson H; Wilander E; Alfano RM; Springall D; Battezzati PM; Polak JM; Coggi G
Cancer; 1994 Jul; 74(1):134-41. PubMed ID: 7911734
[TBL] [Abstract][Full Text] [Related]
3. Reduced Retinoblastoma Protein Expression Is Associated with Decreased Patient Survival in Medullary Thyroid Cancer.
Valenciaga A; Grubbs EG; Porter K; Wakely PE; Williams MD; Cote GJ; Vasko VV; Saji M; Ringel MD
Thyroid; 2017 Dec; 27(12):1523-1533. PubMed ID: 29105562
[TBL] [Abstract][Full Text] [Related]
4. Bcl-2 and c-Myc, but not bax and p53, are expressed during human medullary thyroid tumorigenesis.
Wang DG; Liu WH; Johnston CF; Sloan JM; Buchanan KD
Am J Pathol; 1998 Jun; 152(6):1407-13. PubMed ID: 9626044
[TBL] [Abstract][Full Text] [Related]
5. bcl-2, p53 and proliferating cell nuclear antigen expression is related to the degree of differentiation in thyroid carcinomas.
Pollina L; Pacini F; Fontanini G; Vignati S; Bevilacqua G; Basolo F
Br J Cancer; 1996 Jan; 73(2):139-43. PubMed ID: 8546897
[TBL] [Abstract][Full Text] [Related]
6. Medullary thyroid microcarcinoma: a clinicopathologic retrospective study of 38 patients with no prior familial disease.
Guyétant S; Dupre F; Bigorgne JC; Franc B; Dutrieux-Berger N; Lecomte-Houcke M; Patey M; Caillou B; Viennet G; Guerin O; Saint-Andre JP
Hum Pathol; 1999 Aug; 30(8):957-63. PubMed ID: 10452509
[TBL] [Abstract][Full Text] [Related]
7. Prognostic variables and calcitonin in medullary thyroid cancer.
Clark JR; Fridman TR; Odell MJ; Brierley J; Walfish PG; Freeman JL
Laryngoscope; 2005 Aug; 115(8):1445-50. PubMed ID: 16094121
[TBL] [Abstract][Full Text] [Related]
8. Expression of Pax-8, p53 and bcl-2 in human benign and malignant thyroid diseases.
Puglisi F; Cesselli D; Damante G; Pellizzari L; Beltrami CA; Di Loreto C
Anticancer Res; 2000; 20(1A):311-6. PubMed ID: 10769673
[TBL] [Abstract][Full Text] [Related]
9. Multivariate analysis of prognostic factors in sporadic medullary carcinoma of the thyroid. A retrospective study of 109 consecutive patients.
Scopsi L; Sampietro G; Boracchi P; Del Bo R; Gullo M; Placucci M; Pilotti S
Cancer; 1996 Nov; 78(10):2173-83. PubMed ID: 8918412
[TBL] [Abstract][Full Text] [Related]
10. Expression of bcl-2, c-erbB-2, p53, and p21 (waf1-cip1) protein in thyroid carcinomas.
Soda G; Antonaci A; Bosco D; Nardoni S; Melis M
J Exp Clin Cancer Res; 1999 Sep; 18(3):363-7. PubMed ID: 10606183
[TBL] [Abstract][Full Text] [Related]
11. Expression of cdc25B and cdc25A in medullary thyroid carcinoma: cdc25B expression level predicts a poor prognosis.
Ito Y; Yoshida H; Tomoda C; Uruno T; Takamura Y; Miya A; Kobayashi K; Matsuzuka F; Kuma K; Nakamura Y; Kakudo K; Miyauchi A
Cancer Lett; 2005 Nov; 229(2):291-7. PubMed ID: 16095809
[TBL] [Abstract][Full Text] [Related]
12. SSTR2A expression in medullary thyroid carcinoma is correlated with longer survival.
de Vries LH; Lodewijk L; Willems SM; Dreijerink KMA; de Keizer B; van Diest PJ; Schepers A; Bonenkamp HJ; van Engen-van Grunsven IACH; Kruijff S; van Hemel BM; Links TP; Nieveen van Dijkum EJM; van Eeden S; Valk GD; Borel Rinkes IHM; Vriens MR
Endocrine; 2018 Dec; 62(3):639-647. PubMed ID: 30128959
[TBL] [Abstract][Full Text] [Related]
13. Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: a 10-year follow-up study.
Elisei R; Cosci B; Romei C; Bottici V; Renzini G; Molinaro E; Agate L; Vivaldi A; Faviana P; Basolo F; Miccoli P; Berti P; Pacini F; Pinchera A
J Clin Endocrinol Metab; 2008 Mar; 93(3):682-7. PubMed ID: 18073307
[TBL] [Abstract][Full Text] [Related]
14. Medullary thyroid carcinoma: clinical characteristics, treatment, prognostic factors, and a comparison of staging systems.
Kebebew E; Ituarte PH; Siperstein AE; Duh QY; Clark OH
Cancer; 2000 Mar; 88(5):1139-48. PubMed ID: 10699905
[TBL] [Abstract][Full Text] [Related]
15. [Prognostic factors of survival without clinical recurrences in medullary thyroid carcinoma: apropos of 52 operated cases].
Raffaitin P; Hamy A; Mirallie E; Meurette G; Duplessis R; Lemeunier P; Murat A; Le Bodic M; Le Neel JC; Paineau J; Visset J
Ann Endocrinol (Paris); 1999 Dec; 60(6):435-42. PubMed ID: 10617796
[TBL] [Abstract][Full Text] [Related]
16. Lymph node metastases and elevated postoperative calcitonin: Predictors of poor survival in medullary thyroid carcinoma.
Siironen P; Hagström J; Mäenpää HO; Louhimo J; Arola J; Haglund C
Acta Oncol; 2016; 55(3):357-64. PubMed ID: 26339947
[TBL] [Abstract][Full Text] [Related]
17. "Atypical" medullary thyroid carcinoma with little or no calcitonin expression.
Schmid KW; Ensinger C
Virchows Arch; 1998 Sep; 433(3):209-15. PubMed ID: 9769123
[TBL] [Abstract][Full Text] [Related]
18. Medullary thyroid carcinoma: clinical features and long-term follow-up of seventy-eight patients treated between 1969 and 1986.
Girelli ME; Nacamulli D; Pelizzo MR; De Vido D; Mian C; Piccolo M; Busnardo B
Thyroid; 1998 Jun; 8(6):517-23. PubMed ID: 9669290
[TBL] [Abstract][Full Text] [Related]
19. Mutation of the RET proto-oncogene is correlated with RET immunostaining in subpopulations of cells in sporadic medullary thyroid carcinoma.
Eng C; Thomas GA; Neuberg DS; Mulligan LM; Healey CS; Houghton C; Frilling A; Raue F; Williams ED; Ponder BA
J Clin Endocrinol Metab; 1998 Dec; 83(12):4310-3. PubMed ID: 9851769
[TBL] [Abstract][Full Text] [Related]
20. [Prognostic value of clinical, histopathological and immunohistochemical features in medullary thyroid cancer].
Ríos A; Rodríguez JM; Febrero B; Acosta JM; Torregrosa N; Parrilla P
Med Clin (Barc); 2012 Sep; 139(7):277-83. PubMed ID: 22032817
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
